BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Russian billionaire says 12-hour days and 6-day workweeks could help save the economy - 2Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- 3Investigating the Advantages of a Bank account: A Complete Aide
- 4Illumina unveils dataset to speed up AI-powered drug discovery
- 5Moldova says Russian drones violated airspace
- Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- EU delegation urges China to tighten export controls
- Medical team successfully delivers baby and removes massive tumor
- Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- Ergonomic Office Seats for Work spaces
- Vote In favor of Your Favored Menial helper Administration
- Ukraine's new defense minister just outlined how dire its troop shortage has become
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
